scispace - formally typeset
M

Marianne Debré

Researcher at Necker-Enfants Malades Hospital

Publications -  61
Citations -  6318

Marianne Debré is an academic researcher from Necker-Enfants Malades Hospital. The author has contributed to research in topics: Immunodeficiency & Population. The author has an hindex of 37, co-authored 61 publications receiving 5785 citations. Previous affiliations of Marianne Debré include Louisiana State University in Shreveport & Paris Descartes University.

Papers
More filters
Journal ArticleDOI

Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency

TL;DR: After nearly 10 years of follow-up, gene therapy was shown to have corrected the immunodeficiency associated with SCID-X1 and may be an option for patients who do not have an HLA-identical donor for hematopoietic stem-cell transplantation and for whom the risks are deemed acceptable.
Journal ArticleDOI

Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage

TL;DR: Activated PI3K-δ syndrome (APDS), a PID associated with a dominant gain-of-function mutation in which lysine replaced glutamic acid at residue 1021 (E1021K) in the p110δ protein, the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ), encoded by the PIK3CD gene is described.
Journal ArticleDOI

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

TL;DR: Although most patients initially respond to etanercept, this initial response is not always followed by sustained improvement over longer periods of time, and the higher rate of treatment failure in the group with systemic-onset JIA indicates that these patients in particular may require alternative treatments.
Journal ArticleDOI

Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura

TL;DR: The infusion of Fcγ fragments is an efficient treatment of acute ITP in children and strengthens the hypothesis that F cγR blockade is the main mechanism of action of IVIG in ITP, although other immunoregulatory mechanisms triggered by the presence of increased sCD16 concentrations in serum could be involved in the clinical benefit observed.